ClinicalTrials.gg
RecruitingNCT06377371Updated Feb 27, 2026

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

A Phase 4 interventional study of Brain Imaging with [Cu64]DOTATATE and Radio-guided Surgery With Neoprobe Utilization in Meningioma, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
74th of 107
20 · median 30
Started
2024
with 4 others
Phase 4
2 of 129
2 open now
Primary completion
2027-01
later than 8 of 37 live
Registered
118th of 129
by date
Lead sponsor
4 of 129
Weill Medical College of Cornell University

Among the 129 studies in Meningioma with a site in United States, this one is the 74th largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 4, reaches primary completion later than 8 of the 37 other live ones, and was the 118th registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

The study team hypothesizes that it is feasible to intraoperatively detect tumor following [CU64]DOTATATE injection using the gamma probe device.

Read the detailed description

Objectives:

Primary objectives: The primary objective of this pilot study is to evaluate the feasibility of intraoperative tumor detection using [Cu64]DOTATATE. The study team further wants to validate the gamma count measurements using pre- and post-operative Positron Emission Tomography (PET) standardized uptake value (SUV) .

Secondary Objectives: To correlate intraoperative tracing findings with from pathology markers ( World Health Organization grade (WHO grade), Ki-67, Somatostatin Receptor 2 expression (SSTR2A expression), Estrogen receptor expression (ER expression), Progesterone receptor expression (PR expression)) using samples obtained as part of routine surgical care. To evaluate the correlation of post resection gamma count with longitudinal PET follow up.

Exploratory objectives: To establish best practices for integration of intraoperative tumor tracing using the neoprobe into the surgical workflow. To determine surgical candidates who will benefit most from intraoperative tracing based on tumor location, MRI features, etc.

Overall Design:

This is a single-center prospective observational pilot study to determine the feasibility of using [Cu64]DOTATATE for intraoperative tumor detection. 20 patients diagnosed with meningioma by conventional magnetic resonance imaging (MRI) who are candidates for surgical resection will be enrolled. Enrollment will be facilitated by colleagues in the neurosurgery department (also co- investigators on this study) with whom the PI has had several years of collaboration and an ongoing referral stream (6pprox.. 5 patients per week).

Patients will subsequently undergo pre-operative [Cu64]DOTATATE PET/MRI 12-24 hours prior to surgery. Given that [Cu64]DOTATATE has a much longer half-life compared to [Ga68]DOTATATE, it is uniquely suited for this application, allowing the patient to be injected once with the clinically approved dose, undergo immediate Positron Emission tomography scan and magnetic resonance imaging scan (PET/MRI) or Positron Emission tomography scan and computed tomography scan (PET/CT), and undergo resection the following day with sufficient radiotracer in situ for radio-guided surgery (RGS).

During the operation, the neurosurgeon will make a number of measurements using the neoprobe (available at our institution and currently in frequent routine clinical use for intraoperative sentinel node detection; commonly used for breast cancer, melanoma, oral cancer):

  1. After exposing the tumor, and immediately before removal, tumor counts will be documented with the neoprobe. This count will be correlated with preoperative [Cu64]DOTATATE SUV to evaluate the relationship between radiographic radiotracer uptake and intraoperative radioactivity of the tumor.
  2. After removing all tumor that can be removed safely, the surgeon will grade whether they feel they obtained a gross total resection (GTR) or whether tumor was left behind (subtotal resection (STR), e.g. because the surgeon had to leave behind tumor attached to critical structure). In case of STR, the neoprobe will be used to measure counts in the remaining tumor. In case of presumed GTR, the neoprobe will be used to measure counts in the resection cavity. This second count will be correlated with post-operative [Cu64]DOTATATE SUV to evaluate the effectiveness of this method in evaluating residual tumor.

These steps will not alter the regular course of the surgery in any way. Patients will have two follow-up points after the surgery: 1) at 6 weeks to 3 months post-op and 2) at 6 months to 12 months post-op. Patients will be clinically examined and will undergo repeat [Cu64]DOTATATE PET/MRI or PET/CT during these follow up visits, as standard of care, with radiotracer dosage being funded by the study for the 1st follow up scan, and determined standard of care for the 2nd follow up scan.

03

Conditions studied

  • Meningioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
  • Patients with to somatostatin analogs
  • Patients with to conventional MRI
  • Patients with prior history of cranial radiation therapy
  • Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patients with MRI findings compatible with meningioma who have an indication for surgery

    A diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.

    Diagnostic Test: Brain Imaging with [Cu64]DOTATATE · Procedure: Radio-guided Surgery With Neoprobe Utilization

Interventions

  • Diagnostic testBrain Imaging with [Cu64]DOTATATE

    Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.

  • ProcedureRadio-guided Surgery With Neoprobe Utilization

    After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.

06

What researchers measure

Primary outcomes

  1. Preoperative [Cu64]DOTATATE PET SUV

    preoperative lesion \[Cu64\]DOTATATE PET SUV

    Time frame: At time of enrollment

  2. 1st Post-operative [Cu64]DOTATATE PET SUV

    6 weeks to 3 months follow up post operative \[Cu64\]DOTATATE PET SUV

    Time frame: 3 months

  3. 2nd Post-operative [Cu64]DOTATATE PET SUV

    6 months to 12 months follow up post operative \[Cu64\]DOTATATE PET SUV

    Time frame: 1 year

  4. MRI Size Measurements

    preoperative size measurements based on Response Assessment in Neuro-Oncology (RANO) guidelines

    Time frame: At time of enrollment

  5. GTR vs STR Assessment

    postoperative MRI-based assessment of GTR versus STR by a neuroradiologist, as determined by the presence or absence of nodular dural-based enhancement on post contrast 3D T1-weighted MR imaging and direct comparison to preoperative MRI.

    Time frame: 6 weeks- 3 months

  6. MRI Progression Assessment

    follow-up MRI assessment of progression based on RANO guidelines

    Time frame: 6-12 months

  7. Target Lesion Neoprobe Count

    Neoprobe count of the target lesion prior to resection.

    Time frame: At time of enrollment

  8. Subtotal Neoprobe Count

    Neoprobe count of the subtotally resected tumor or the resection cavity in case of presumed GTR post resection.

    Time frame: At time of enrollment

  9. Reference Background Neoprobe Count

    Neoprobe count of the reference background measured at least 1 cm away from the tumor (measured in at least two locations depending on the operative field)

    Time frame: At time of enrollment

Secondary outcomes

  1. SSTR2 expression

    immunohistochemistry analysis of SSTR2 expression in the resected tumor

    Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).

  2. WHO grade

    determined histomorphologically based on pathologist's assessment of resected tumor tissue.

    Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).

  3. Ki67 Proliferation Index

    Ki67 Proliferation Index (percentage of positively stained tumor cells among the total number of malignant cells assessed).

    Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).

  4. ER/PR expression

    determined based on pathologist's assessment of resected tumor tissue.

    Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 22, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06377371
Collaborators
Curium US LLC
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Sep 11, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Jana Ivanidze, MD/PhD
Contact
jai9018@med.cornell.edu
212-746-4587
Alexis Watson
Contact
alw4020@med.cornell.edu
646-962-2347
Jana Ivanidze, MD/PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion